gemcitabine has been researched along with Gallbladder Neoplasms in 194 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (1.55) | 18.2507 |
| 2000's | 54 (27.84) | 29.6817 |
| 2010's | 108 (55.67) | 24.3611 |
| 2020's | 29 (14.95) | 2.80 |
| Authors | Studies |
|---|---|
| Fukushima, K; Hayashi, H; Hosoda, K; Kobayashi, R; Kubota, K; Motoyama, H; Notake, T; Shimizu, A; Soejima, Y; Sugenoya, S; Yasukawa, K | 1 |
| Chen, T; Chen, W; Chen, X; Hu, X; Jiang, C; Lin, R; Wang, X; Xu, S | 1 |
| Hu, W; Li, K; Liu, K; Qu, L | 1 |
| Kai, H; Lee, K; Maruyama, K; Masuike, Y; Mizojiri, G; Nagasawa, Y; Ohata, M; Oka, H; Sada, A; Takeda, K; Takeshita, A; Watanabe, S | 1 |
| Aoyama, S; Hata, T; Hiraki, M; Ikeshima, R; Katsura, Y; Katsuyama, S; Kihara, Y; Kinoshita, M; Masuzawa, T; Muneta, M; Murata, K; Ohmura, Y; Shinke, G; Sugimura, K; Takeda, Y | 1 |
| Huang, W; Lai, J; Li, R; Li, X; Lin, Z; Tan, J; Wang, W; Yang, S | 1 |
| Bramwell, LG; Cheung, K; Falchook, GS; Janku, F; Javle, MM; Johansen, MJ; Madden, T; Maier, G; Pant, S; Saeki, K; Sen, S; Subach, RA; Subbiah, V; Suzuki, T; Wages, DS; Way, T; Wheeler, CA | 1 |
| Guo, M; He, M; Liu, Y; Wang, H; Yang, L; Zhan, M; Zhang, W | 1 |
| Bizama, C; Buchegger, K; Espinoza, K; García, P; Ili, C; Leal, P; Obreque, J; Repetto, G; Roa, JC; Rosa, L; Suárez, F; Vergara-Gómez, L; Weber, H; Zhong, J | 1 |
| Hong, JY; Kim, ST; Lim, SH; Park, JO; Park, YS | 1 |
| Bai, X; Chen, J; Dong, L; He, X; Huang, J; Zhang, W; Zhou, S | 1 |
| Cheng, H; Ding, J; Ma, F; Sun, Y; Wang, S; Yu, X; Zhou, D | 1 |
| Bhatnagar, S; Deo, SV; Iyer, VK; Kalyan Mohanti, B; Kumar Sahoo, R; Kumar Shukla, N; Kumar, R; Kumar, S; Mishra, S; Pal Chaudhary, S; Pal, S; Pathy, S; Raina, V; Ranjan Dash, N; Sahni, P; Sharma, A; Sreenivas, V; Thulkar, S | 1 |
| Dong, D; Dong, X; Fan, Y; Geng, Q; Hu, Y; Jing, J; Li, E; Shi, Y; Wang, C; Wu, Y | 1 |
| Chen, W; He, M; Huang, S; Huang, X; Jiang, C; Lin, R; Liu, Q; Mohan, M; Shen, H; Shi, Y; Wang, J; Xu, S; Yang, L; Zhan, M | 1 |
| Qin, G; Xu, Q; Xue, Z; Yang, B; Zhu, X | 1 |
| Lin, W; Lu, B; Shi, L; Yu, J; Zhao, Y | 1 |
| Bo, X; Gao, Z; Li, M; Liu, H; Lu, P; Nan, L; Ni, X; Shen, S; Suo, T; Wang, C; Wang, J; Wang, Y; Xin, Y; Zhang, D | 1 |
| Edeline, J | 1 |
| Al-Batran, SE; Bankstahl, US; Bechstein, WO; Goetze, TO; Keck, T; Königsrainer, A; Lang, SA; Pauligk, C; Piso, P; Vogel, A | 1 |
| Alfaro, F; Bizama, C; Boekstegers, F; Cerda-Infante, J; Dávila-López, M; Espinoza, JA; García, P; Kato, S; Lagos, M; Leal, P; Leiva-Acevedo, C; Lorenzo-Bermejo, J; Montecinos, VP; Parra, Z; Roa, JC; Romero, D; Rosa, L; Sánchez, M; Weber, H | 1 |
| André, T; Bekaii-Saab, T; Bridgewater, J; Cunningham, D; Goldstein, D; Jensen, LH; Knox, JJ; Koeberle, D; Lopes, A; Malka, D; McNamara, MG; Moehler, M; Okusaka, T; Shannon, J; Valle, JW; Wagner, AD; Wasan, H | 1 |
| Kumar, T; Pandey, M; Soni, K | 1 |
| Fan, YZ; Li, XP; Pan, MS; Sun, W; Wang, FT; Wang, H; Wang, QW | 1 |
| Jiang, WD; Qiu, L; Wang, HY; Wu, JC; Zhang, GF | 1 |
| Lu, Y; Ruan, Y; Wang, L | 1 |
| Aoyama, Y; Hayashi, K; Hayashi, Y; Imafuji, H; Kato, T; Matsuo, Y; Morimoto, M; Naitoh, I; Ogawa, R; Omi, K; Saito, K; Takahashi, H; Takiguchi, S; Tsuboi, K; Ueda, G | 1 |
| Chen, K; Du, Z; Feng, R; Li, R; Qi, L; Ye, J; Yu, L; Zhai, W | 1 |
| Fujimura, A; Ichimiya, S; Imaizumi, A; Koga, S; Nagao, S; Nakamura, M; Nakayama, K; Oda, Y; Onishi, H; Oyama, Y; Sakihama, K | 1 |
| Byeon, S; Hong, JY; Jang, KT; Kang, WK; Kim, H; Kim, J; Kim, ST; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS | 1 |
| Chu, PY; Lai, HY; Liang, HY; Liu, YB; Shen, WJ; Wang, JM; Wang, WJ; Zhang, F | 1 |
| Chen, W; Liu, Q; Long, MM; Mohan, M; Shi, YH; Wang, H; Wang, J; Xu, SW; Zhan, M | 1 |
| Chang, HM; Cho, H; Hyung, J; Kim, BJ; Kim, KP; Kim, MH; Lee, SK; Lee, SS; Park, DH; Park, JH; Park, SJ; Ryoo, BY; Seo, DW; Song, TJ; Yoo, C | 1 |
| Arakawa, Y; Ikemoto, T; Imura, S; Iwahashi, S; Morine, Y; Saito, YU; Shimada, M; Yamada, S | 1 |
| Belkouz, A; Coelen, RJS; de Groot, JWB; Dierks, J; Gaspersz, MP; Groot Koerkamp, B; Klümpen, H; Meijer, WG; Otten, HM; Pruijt, JFM; Rentinck, M; Smit, JM; Ten Oever, D; Ten Tije, AJ; van Gulik, TM; van Spronsen, DJ; van Voorthuizen, T; van Vugt, JLA; Wilmink, JW | 1 |
| Aglietta, M; Aprile, G; Avallone, A; Cagnazzo, C; Cavalloni, G; Cereda, S; Doglioni, C; Fenocchio, E; Frattini, M; Gammaitoni, L; Leone, F; Martin, V; Nasti, G; Peraldo-Neia, C; Reni, M; Satolli, MA; Spadi, R; Venesio, T | 1 |
| Bell-McGuinn, K; Cristea, M; Fleming, GF; Gray, HJ; Luo, Y; Martin, LP; McKee, MD; Munasinghe, W; Sullivan, D; Xiong, H | 1 |
| Hakamada, K; Ishido, K; Kimura, N; Kudo, D; Mitsuhashi, Y; Toyoki, Y; Wakiya, T; Yakoshi, Y | 1 |
| Hasuo, K; Jin, Y; Kakazu, A; Komori, K; Masuda, M; Mikayama, Y; Watanabe, T | 1 |
| Maithel, SK; Zaidi, MY | 1 |
| Engineer, R; Goel, M; Kumar, S; Majumdar, S; Mandavkar, S; Mehta, S; Ostwal, V; Patkar, S; Ramaswamy, A; Swami, R | 1 |
| Abdel-Rahman, O; Elhalawani, H; Elsayed, Z | 1 |
| Chen, W; He, M; Liu, Q; Long, MM; Wang, H; Wang, J; Xu, SW; Yang, LH; Yang, RM; Zhan, M | 1 |
| Bharti, JN; Soni, SC; Sureka, B; Varshney, VK | 1 |
| Bajpai, P; Pandey, P; Pathak, N; Sayyed, U; Siddiqui, MH; Tiwari, RK | 1 |
| Rao, M; Soni, SC; Sureka, B; Varshney, VK | 1 |
| Higashi, Y; Hirayama, K; Maruo, H; Nakamura, K; Shibasaki, Y; Shimizu, Y; Shoji, T; Tsuyuki, H; Yamazaki, M | 1 |
| Fischer, M; Kirstein, MM; Kratzel, AM; Manns, MP; Mederacke, YS; Schweitzer, N; Vogel, A | 1 |
| Deng, Z; Li, X; Liu, Y; Lu, Y; Ma, C; Tian, L; Wang, J; Xu, L; Yang, T; Yao, W; Zhang, J | 1 |
| Hu, Z; Huang, Y; Sun, Q; Wang, W; Yang, Q; Zhang, L; Zhang, Y; Zheng, H | 1 |
| Kim, HS; Kim, K; Lee, JK; Lee, KH; Lee, KT; Park, JK; Song, BG | 1 |
| Autorino, R; Bisello, S; Brandi, G; Buwenge, M; Cammelli, S; Cellini, F; Cilla, S; Deodato, F; Macchia, G; Mattiucci, GC; Morganti, AG; Palloni, A; Tagliaferri, L; Valentini, V | 1 |
| Kano, M; Nakau, M; Suzaki, S; Tachibana, T; Yamamoto, T; Yanagibashi, K | 1 |
| Takeuchi, K; Tamura, T | 1 |
| Fujiwara, Y; Furukawa, K; Haruki, K; Iwase, R; Misawa, T; Ohashi, T; Shiba, H; Uwagawa, T; Yanaga, K | 1 |
| Abou-Alfa, GK; Capanu, M; Chou, JF; Chung, KY; Gansukh, B; Katz, SS; Lee, JK; Ma, J; O'Reilly, EM; Reidy-Lagunes, D; Saltz, LB; Segal, NH; Shia, J; Yu, KH | 1 |
| Ikeda, M; Morizane, C; Okusaka, T | 1 |
| Ajiki, T; Asari, S; Fukumoto, T; Goto, T; Kido, M; Ku, Y; Matsumoto, I; Murakami, S; Ohtsubo, I; Okazaki, T; Shinozaki, K; Shinzeki, M; Yoshida, Y | 1 |
| Kaiho, T; Kobayashi, S; Nishimura, M; Okamoto, R; Okaniwa, A; Shimizu, W; Shinmura, K; Tsuchiya, S; Yanagisawa, S | 1 |
| Kaiho, T; Kobayashi, S; Miyazaki, M; Nishimura, M; Nomura, S; Okamoto, R; Okaniwa, A; Shinmura, K; Tsuchiya, S; Yanagisawa, S | 1 |
| Adikrisna, R; Arii, S; Irie, T; Matsumura, S; Nakamura, N; Tanaka, S | 1 |
| Chen, T; He, M; Ji, F; Li, F; Shen, HJ; Shi, WJ; Wang, J; Xu, M; Yang, C; Zhu, HY | 1 |
| Banno, S; Imai, H; Kawai, H; Miura, N; Nobata, H; Suzuki, K; Wakamatsu, R; Yamada, Y | 1 |
| André, T; Assenat, E; Blanc, JF; Boucher, E; Cervera, P; de la Fouchardière, C; Dollinger, M; Ducreux, M; Faivre, S; Fartoux, L; Foulon, S; Grenier, J; Greten, TF; Hahn, P; Hammel, P; Heinemann, V; Herrmann, T; Malka, D; Pignon, JP; Rosmorduc, O; Rousseau, V; Seufferlein, T; Trarbach, T; Viret, F; Wendum, D | 1 |
| Feng, J; Huang, X; Huang, Z; Li, Y | 1 |
| Abe, T; Ensako, T; Hino, K; Nakamura, M; Nakashima, H; Yoshida, K | 1 |
| Abrams, TA; Allen, JN; Baran, A; Blaszkowsky, LS; Borger, DR; Clark, JW; Connolly, GC; Faris, JE; Fuchs, C; Goyal, L; Harris, DJ; Herr, M; Hezel, AF; Hyrien, O; Iafrate, AJ; Khorana, AA; Murphy, JE; Ng, K; Noel, MS; Regan, E; Ryan, DP; Sheehan, S; Yurgelun, M; Zheng, H; Zhu, AX | 1 |
| Hong, DF; Hu, ZM; Huang, DS; Shang, MJ; Wu, WD; Zhang, CW; Zhao, DJ | 1 |
| Beohou, E; Bonnetain, F; Borg, C; Cleau, D; Demarchi, M; Dobi, E; Fein, F; Fiteni, F; Fratté, S; Jary, M; Kim, S; Monnien, F; Nerich, V; Nguyen, T; Pivot, X | 1 |
| Adachi, T; Goto, A; Hirata, T; Ishimine, Y; Kasai, K; Kondo, Y; Naito, T; Yabana, T | 1 |
| Azam, S; Batra, U; Choudhury, KD; Doval, DC; Kumar, K; Mehta, A; Pruthi, A | 1 |
| Ide, T; Ide, Y; Kai, K; Kitahara, K; Koga, H; Miyoshi, A; Nakamura, H; Nakamura, J; Noshiro, H; Okumura, T | 1 |
| Berie, L; Denzer, U; Distelrath, A; Dollinger, MM; Duerr, EM; Ebert, MP; Galle, PR; Geissler, M; Kaiser, AK; Kanzler, S; Kolligs, FT; Lammert, F; Lindig, U; Lohse, A; Lubomierski, N; Maderer, A; Moehler, M; Sauvigny, C; Schadmand-Fischer, S; Schimanski, C; Schütz, M; Trojan, J; Wachtlin, D; Woerns, M; Zimmermann, S | 1 |
| Gao, H; Han, M; Han, Y; Jiang, Q; Peng, J; Wang, C; Xie, J | 1 |
| Jiang, X; Li, B; Wang, J; Xia, N; Yu, Y | 1 |
| Karasawa, H; Katagiri, M; Katayose, Y; Morikawa, T; Motoi, F; Naito, T; Sato, J; Unno, M; Yabuuchi, S | 1 |
| Fiaschi, AI; Francini, E; Laera, L; Marrelli, D; Petrioli, R; Roviello, F; Roviello, G | 1 |
| Dawood, S; Kulkarni, S; Ramadwar, M; Rastogi, S; Sheth, V; Shrikhande, SV; Singh, A; Sirohi, B; Talole, S | 1 |
| Alberts, SR; Ben-Josef, E; Blanke, CD; Corless, CL; Dawson, LA; El-Khoueiry, AB; Guthrie, KA; Lowy, AM; Micetich, KC; Siegel, AB; Thomas, CR; Thomas, MB; Zalupski, MM | 1 |
| Fujiwara, S; Hirayama, A; Horii, A; Kudo, C; Matsumura, N; Mizuguchi, Y; Motoi, F; Nakano, T; Saiki, Y; Soga, T; Sunamura, M; Unno, M | 1 |
| Arnold, D; Bridgewater, J; Goldstein, D; Jensen, LH; Klümpen, HJ; Lohse, AW; Nashan, B; Primrose, J; Schrum, S; Shannon, J; Stein, A; Vettorazzi, E; Wege, H | 1 |
| Aguayo, G; Bizama, C; Espinoza, JA; García, P; Leal, JL; Macanas, P; Nervi, B; Riquelme, I; Roa, JC; Viñuela, E; Weber, H | 1 |
| Aglietta, M; Amatu, A; Aprile, G; Belli, C; Cagnazzo, C; Cereda, S; Ciuffreda, L; Fasola, G; Filippi, R; Leone, F; Marino, D; Montano, M; Nasti, G; Reni, M; Siena, S; Spadi, R | 1 |
| Dodagoudar, C; Doval, DC; Goel, V; Goyal, P; John, MC; Mahanta, A; Patnaik, N; Singh, S; Talwar, V; Tiwari, S; Upadhyay, A | 1 |
| Ajiki, T; Asari, S; Fukumoto, T; Goto, T; Kido, M; Kinoshita, H; Ku, Y; Matsumoto, T; Murakami, S; Shinozaki, K; Toyama, H | 1 |
| Furukawa, T; Muto, T; Takahashi, H; Tanaka, K | 1 |
| Chiba, R; Kaiho, T; Kobayashi, S; Mun, Y; Nishimura, M; Okamoto, R; Okaniwa, A; Shinmura, K; Tsuchiya, S; Yanagisawa, S | 1 |
| Goel, M; Gupta, S; Jandyal, S; Ostwal, V; Pande, N; Patkar, S; Ramadwar, M; Ramaswamy, A; Sahu, A; Shetty, N | 1 |
| Anamalai, M; Julka, PK; Kumaran, D; Nambirajan, A; Velu, U | 1 |
| Bang, S; Cha, J; Kim, HM; Lee, KJ; Park, SW; Seong, J; Song, SY; Yi, SW | 1 |
| Andley, M; Maharshi, V; Nagar, P; Rehan, HS | 1 |
| Aoki, H; Kanaya, N; Morihiro, T; Takeuchi, H; Yamasaki, R | 1 |
| Handa, K; Kaida, H; Nagano, H; Sato, M; Tomita, A; Watanabe, R; Yoshioka, S | 1 |
| Akita, H; Fujiwara, Y; Fukui, K; Gotoh, K; Kobayashi, S; Marubashi, S; Sakon, M; Takahashi, H; Teshima, T; Tomokuni, A; Yamada, T | 1 |
| Fujii, Y; Fujita, H; Fujita, J; Funaki, H; Kaida, D; Kinami, S; Kosaka, T; Miura, S; Nakano, Y; Ohnishi, T; Tomita, Y; Ueda, N | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Kawamoto, K; Mori, M; Nagaoka, S; Noda, T; Umeshita, K; Wada, H; Yamada, D | 1 |
| Fukuda, S; Harada, T; Hiraki, S; Kanesada, K; Tada, K | 1 |
| Araki, H; Choda, Y; Harano, M; Idani, H; Ishida, M; Kanazawa, T; Matsukawa, H; Mimura, N; Ninomiya, M; Ogawa, T; Ojima, Y; Okajima, M; Satoh, D; Shiozaki, S; Sumitani, D | 1 |
| Asai, K; Fukunaga, H; Hiratsuka, M; Murata, M; Saso, K; Sawami, H; Suzuki, R; Tanaka, N; Yamada, M; Yamamoto, M | 1 |
| Banavali, S; Bhargava, P; Kannan, S; Mirani, J; Nashikkar, C; Ostwal, V; Pinninti, R; Ramaswamy, A | 1 |
| Ide, T; Kitajima, Y; Kohya, N; Mitsuno, M; Miyazaki, K; Ohtaka, K; Sato, K | 1 |
| Arai, M; Fujita, Y; Fujitani, S; Fukuda, K; Horiki, N; Iizuka, Y; Ishii, N; Suzuki, S; Tsukamoto, M | 1 |
| Pan, BR; Qin, TJ; Ruan, ZP; Yun, J; Zhang, LX; Zhao, XH | 1 |
| Abou-Alfa, GK; Blumgart, LH; Capanu, M; D'Angelica, M; Dematteo, RP; Duffy, A; Fong, Y; Huitzil, D; Jarnagin, W; O'Reilly, EM | 1 |
| Ajiki, T; Fujino, Y; Fujita, T; Ku, Y; Kuroda, Y; Matsumoto, I; Matsumoto, T; Mita, Y; Morimoto, H; Suzuki, Y; Takase, S | 1 |
| Kijima, H; Kusumi, T; Nakamura, M; Nishime, C; Ohnishi, Y; Sato, F; Suemizu, H; Tamaoki, N; Ueyama, Y; Yamazaki, H | 1 |
| Alberts, SR; Fitch, TR; Foster, NR; Jaslowski, AJ; Kugler, JW; McWilliams, RR; Quevedo, FJ; Sande, JR | 1 |
| Akashi, K; Arita, S; Baba, E; Hirano, G; Isobe, T; Kusaba, H; Makiyama, A; Nakano, S; Qin, B; Shibata, Y; Uchino, K | 1 |
| Frumovitz, M; Han, LY; Rashid, A; Ricks, AM | 1 |
| DattaGupta, S; Deo, S; Dwary, A; Garg, P; Mohanti, B; Pal, S; Raina, V; Rath, G; Sahni, P; Sharma, A; Shukla, N; Thulkar, S | 1 |
| Byun, JH; Hwang, IG; Jang, JS; Kim, BS; Kim, SY; Kim, YH; Lee, KH; Lee, MA; Lee, SJ; Lim, HY; Oh, SC; Oh, SJ; Park, E; Song, HS; Yoo, N; Yoon, S | 1 |
| Behl, S; Behrens, R; Buechner-Steudel, P; Fahlke, J; Fleig, WE; Kleber, G; Kuss, O; Moehler, M; Schmalenberg, H; Wagner, AD; Wein, A | 1 |
| Capelozzi, VL; Galvão, FH; Pestana, JO | 1 |
| Matsuda, A; Matsushita, A; Matsutani, T; Sasajima, K; Uchida, E; Yokoyama, T | 1 |
| Doki, Y; Eguchi, H; Hatano, H; Kitagawa, T; Kobayashi, S; Marubashi, S; Monden, M; Mori, M; Nagano, H; Ohmura, Y; Takeda, Y; Takiuchi, D; Tanemura, M; Tomokuni, A | 1 |
| Lorenz, J; Mössner, J; Wiedmann, M; Wolf, S | 1 |
| Chang, PY; Cheng, MF; Hsieh, CB; Lee, HS; Yao, NS | 1 |
| Adham, M; Bancel, B; Baulieux, J; Cassier, PA; Lombard-Bohas, C; Ponchon, T; Scoazec, JY; Souquet, JC; Thevenet, C; Walter, T | 1 |
| Bifulco, G; Carlomagno, C; De Placido, S; Insabato, L; Lauria, R | 1 |
| Cho, SY; Han, SS; Kim, SH; Kim, TH; Kim, YK; Lee, KW; Lee, WJ; Park, SJ; Woo, SM | 1 |
| Heike, Y; Ikeda, M; Kaida, M; Kojima, Y; Kondo, S; Morita-Hoshi, Y; Morizane, C; Okusaka, T; Soeda, A; Ueno, H; Wakeda, T; Yamaki, Y | 1 |
| Engineer, R; Kishore Shrivastava, S; Mahantshetty, U; Mehta, S; Purandare, N; Rangarajan, V; Wadasadawala, T | 1 |
| Hunabiki, K; Iwadou, H; Kamikawa, Y; Matsuda, T; Watanabe, T; Yoshida, R | 1 |
| Gupta, P; Khanna, AK; Khanna, R; Singh, S | 1 |
| Nakamoto, Y; Ogata, M; Yamamoto, M | 1 |
| Gong, W; He, Z; Jiang, J; Li, X; Qin, R; Shi, C; Tian, R; Wang, M; Wang, X; Zhang, Z | 1 |
| Frank, RC; Lincer, R; Mody, K; Strauss, E | 1 |
| Abahssain, H; Afchain, P; Errihani, H; Ismaili, N; Melas, N; Rabti, HM; Rahali, R | 1 |
| Aglietta, M; Bardelli, A; Casorzo, L; Cavalloni, G; Chiorino, G; Leone, F; Migliardi, G; Penachioni, JY; Peraldo-Neia, C; Pignochino, Y; Risio, M; Sarotto, I | 1 |
| Akagi, K; Dono, K; Fujino, S; Fujita, J; Hata, T; Ikeda, K; Iwazawa, T; Kawanishi, K; Kitada, M; Kitahara, T; Miyake, M; Munakata, K; Nagai, K; Shimano, T; Shimizu, J; Takamoto, K; Watanabe, N; Yanagawa, T | 1 |
| Kametaka, H; Koyama, T; Makino, H; Seike, K | 1 |
| Hashimoto, Y; Kobayashi, H; Kondo, N; Murakami, Y; Nakashima, A; Sakabe, R; Sudo, T; Sueda, T; Uemura, K | 1 |
| Ahmad, SA; Blanke, CD; El-Khoueiry, AB; Gold, PJ; Holcombe, RF; Iqbal, S; Lenz, HJ; Messino, MJ; Rankin, C | 1 |
| Gattuso, P; Groh, V; Kaufman, HL; Plate, J; Prinz, RA; Rao, GS; Spies, T; Xu, X | 1 |
| Handa, K; Hatogai, K; Hibi, T; Higuchi, H; Iwasaki, E; Izumiya, M; Kishino, R; Maeda, N; Mizuki, A; Mukai, K; Nakazawa, A; Seki, E; Shimoyama, Y; Takaishi, H; Takita, M; Tsukada, N | 1 |
| Giannini, OH; González, ME; González, P; Saldaña, B | 1 |
| Jensen, LH | 1 |
| Chang, HM; Chang, JS; Choi, HJ; Jang, JS; Jeung, HC; Kang, HJ; Kang, JH; Kang, WK; Kim, JS; Lee, HW; Lee, J; Lee, MA; Lim, HY; Park, JO; Park, SH; Park, YS; Shin, DB; Sun, JM | 1 |
| Baba, H; Goseki, N; Kuwabara, H; Nakajima, K; Nakamura, H; Sanada, T; Wakabayashi, M | 1 |
| Konishi, M | 1 |
| Ajiki, T; Connolly, K; DiGiovanni, J; Kiguchi, K; Kitamura, T; Lueckgen, A; Ruffino, L | 1 |
| Furuse, J; Kasuga, A; Kitamura, H; Nagashima, F; Takasu, A | 1 |
| Fukuoka, J; Hori, R; Moriyama, M; Nagata, T; Okumura, T; Omura, T; Sawada, S; Sekine, S; Shimada, Y; Tsukada, K; Watanabe, T; Yoshioka, I | 1 |
| Lee, JK; Lee, KH; Lee, KT; Moon, IH; Rhee, JC; Yang, MH; Yang, S | 1 |
| Alexandrescu, S; Becheanu, G; Buica, F; Croitoru, A; Diculescu, M; Dinu, I; Gheorghe, L; Gramaticu, I; Herlea, V; Hrehoret, D; Luca, I; Lupescu, I; Popescu, I; Simionov, I | 1 |
| Furukawa, K; Kato, A; Kimura, F; Miyazaki, M; Ohtsuka, M; Shimizu, H; Takayashiki, T; Takeuchi, D; Yoshidome, H; Yoshitomi, H | 1 |
| Chen, GY; Ding, YB; Liu, JL; Xia, JG; Zhang, DC | 1 |
| Hirano, K; Isayama, H; Ito, Y; Kogure, H; Koike, K; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Toda, N; Yagioka, H; Yamamoto, N | 1 |
| Ahmadzadeh, A; Babaei, M; Elahi, F; Hassanpour, K; Yadollahzadeh, M | 1 |
| Eichelmann, K; Fahlke, J; Hribaschek, A; Kuhn, R; Ridwelski, K; Rudolph, S | 1 |
| Boxberger, F; Brueckl, V; Brueckl, WM; Hahn, EG; Hautmann, M; Hohenberger, W; Jüngert, B; Wein, A | 1 |
| Aziz, Z; Malik, IA; Sethuraman, G; Zaidi, SH | 1 |
| Alfieri, S; Cellini, N; Costamagna, G; Doglietto, GB; Luzi, S; Macchia, G; Morganti, AG; Smaniotto, D; Trodella, L; Valentini, V | 1 |
| Gennatas, K; Gouveris, P; Karatzas, G; Kosmas, C; Margaris, H; Mouratidou, D; Papadoniou, N; Papalambros, E; Papastratis, G; Polyzos, A; Tsavaris, N; Tsipras, H; Tzima, E | 1 |
| Chiba, H; Hirayama, Y; Sagawa, T; Sakamaki, S; Takayanagi, N; Tsuji, Y | 1 |
| Awasthy, BS; Doval, DC; Fuloria, J; Gupta, S; Gupta, SK; Sekhon, JS; Shukla, VK | 1 |
| Hedley, D; Knox, JJ; Moore, MJ; Oza, A; Pond, GR; Siu, LL | 1 |
| Dono, K; Hashimoto, K; Kubota, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Takahashi, H; Umeshita, K; Yamamoto, S | 1 |
| Al-Khatib, H; Alberts, SR; Burgart, L; Cera, PJ; Finch, TR; Flynn, PJ; Knost, JA; Levitt, R; Mahoney, MR; Tschetter, LK; Windschitl, HE | 1 |
| Dai, L; Eng, C; Kindler, HL; Mani, S; Ramanathan, RK; Ramathan, RK; Remick, SC; Wade-Oliver, KT; Wong, MK | 1 |
| Charoentum, C; Moonprakan, S; Napapan, S; Thongprasert, S | 1 |
| Fujii, Y; Yoneto, T; Yoshikawa, K | 1 |
| Jin-Kim, H; Kim, JS; Kim, SH; Kim, YH; Kwon, HC; Oh, SY; Park, JS | 1 |
| Chen, E; Feld, R; Hedley, D; Knox, JJ; Moore, MJ; Nematollahi, M; Oza, A; Pond, GR; Siu, LL; Zhang, J | 1 |
| Drebin, JA; Lin, LL; Linehan, DC; Myerson, R; Picus, J; Solis, J; Strasberg, SM; Tan, B; Thorstad, WL | 1 |
| Eckel, F; Lersch, C; Mayr, M; Schmid, RM; Schulte-Frohlinde, E; von Delius, S | 1 |
| Bahadur, S; Gibbs, J; Javle, M; Litwin, A; Melnyk, M; Nava, H; Shaukat, A | 1 |
| Cho, JY; Lee, DK; Lee, SJ; Nam, JS; Paik, YH; Park, MS; Yoon, DS; Yu, JS | 1 |
| Baba, H; Matsumoto, G; Okamoto, A; Shimada, Y; Tsurta, K | 1 |
| Barajas, O; Gallardo, J; Rubio, B; Villanueva, L | 1 |
| Brouwers, MC; Dingle, BH; Rumble, RB | 1 |
| Julka, PK; Puri, T; Rath, GK | 1 |
| Hada, M; Horiuchi, T; Shinji, H | 1 |
| Berrios, M; Cordova, A; de Aretxabala, X; Gallardo, J; Hepp, J; Leon, J; Maluenda, F; Roa, I; Roa, JC | 1 |
| Badalamenti, G; Cicero, G; Di Leo, R; Fulfaro, F; Gebbia, N; Gulotta, G; Russo, A; Santangelo, D; Tomasello, G; Valerio, MR; Verderame, F | 1 |
| Bajardi, E; Borsellino, N; Colucci, G; Gebbia, V; Giuliani, F; Maiello, E | 1 |
| Ajiki, T; Fujimori, T; Fujita, T; Hirata, K; Hori, H; Horiuchi, H; Kamigaki, T; Kuroda, Y; Mita, Y; Okazaki, T | 1 |
| Egberts, JH; Fändrich, F; Kalthoff, H; Kruse, ML; Schafmayer, C; Schniewind, B; Sipos, B; Tepel, J | 1 |
| Bhargava, P; Blaszkowsky, L; Earle, CC; Fuchs, CS; Kulke, MH; Lehman, N; Meyerhardt, JA; Ryan, DP; Stuart, K; Zhu, AX | 1 |
| Chin, SN; Knox, JJ; Pond, GR; Riechelmann, RP; Townsley, CA | 1 |
| Fakih, M; Gibbs, J; Iyer, RV; Javle, MM; Kepner, J; Kuvshinoff, B; Lawrence, D; Soehnlein, N | 1 |
| Kimura, F; Miyazaki, M; Ohtsuka, M; Seki, N; Shimizu, H; Sugimoto, T; Washiro, M; Yoshidome, H | 1 |
| Fujii, M; Fukatsu, H; Harada, R; Ishida, E; Kawamoto, H; Kurihara, N; Mizuno, O; Nakanishi, T; Ogawa, T; Okada, H; Sakaguchi, K; Tsutsumi, K | 1 |
| Kurosaki, I; Nakadaira, K; Ueki, H | 1 |
| Castro, MP | 1 |
| Fodor, M; Gallardo, J; Gamargo, C; Orlandi, L | 1 |
| Adjei, AA; Erlichman, C | 1 |
| Abruzzo, F; Di Leo, R; Mandina, P; Scarpulla, M; Verderame, F | 1 |
| Lehnert, T; Rudi, J; Stremmel, W; Teufel, A | 1 |
| Ahumada, M; Cortés, C; Gallardo, J; Rubio, B | 1 |
| Ahumada, M; Fodor, M; Gallardo, JO; Gamargo, C; Orlandi, L; Rubio, B; Yáñez, M | 1 |
| Assmann, G; Eckel, F; Lersch, C; Schulte-Frohlinde, E | 1 |
| Bareck, E; Depisch, D; Ploner, M; Puhalla, H; Scheithauer, W; Stiglbauer, W | 1 |
| Rudi, J | 1 |
14 review(s) available for gemcitabine and Gallbladder Neoplasms
| Article | Year |
|---|---|
Update on Chemoresistance Mechanisms to First-Line Chemotherapy for Gallbladder Cancer and Potential Reversal Strategies.
Topics: Cisplatin; Drug Resistance, Neoplasm; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans | 2023 |
[Adjuvant treatment of biliary tract cancers: Who and how?]
Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Gallbladder Neoplasms; Gemcitabine; Humans; Intention to Treat Analysis; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Treatment Outcome | 2020 |
Gallbladder cancer with EGFR mutation and its response to GemOx with erlotinib: a case report and review of literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Mutation; Oxaliplatin; Prognosis; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2020 |
[Cystic Duct Cancer with Postoperative Liver Metastasis That Achieved Complete Response after Gemcitabine Treatment - A Case Report].
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Cholecystectomy; Cystic Duct; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Neoplasm Staging | 2017 |
Updates on Gallbladder Cancer Management.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Gallbladder Neoplasms; Gemcitabine; Hepatectomy; Humans; Laparoscopy | 2018 |
Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Topics: Ampulla of Vater; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Tegafur | 2018 |
[Chemotherapy for gallbladder cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gallbladder Neoplasms; Gemcitabine; Humans; Molecular Targeted Therapy | 2013 |
[Curative resection of stage IV advanced gallbladder cancer following combined treatment with gemcitabine and CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Cholecystectomy; Combined Modality Therapy; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Lymph Node Excision; Lymphatic Metastasis; Neoplasm Staging; Oxonic Acid | 2014 |
[Gallbladder cancer with elevated serum α-fetoprotein, α-fetoprotein-L3, and human chorionic gonadotropin levels].
Topics: Adenocarcinoma; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Chorionic Gonadotropin; Cisplatin; Deoxycytidine; Fatal Outcome; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Middle Aged | 2014 |
[Chemotherapy in gallbladder carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Leucovorin; Mitomycin; Neoplasm Invasiveness; Neoplasm Staging; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2010 |
Adjuvant chemotherapy for resectable biliary tract cancer: current status and future direction.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Prognosis; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
Role of chemotherapy in treatments for biliary tract cancer.
Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
The role of gemcitabine in the treatment of cholangiocarcinoma and gallbladder cancer: a systematic review.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Clinical Trials, Phase II as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Survival Analysis; Treatment Outcome | 2005 |
Chemoradiotherapy in gallbladder cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Palliative Care; Survival Analysis | 2006 |
49 trial(s) available for gemcitabine and Gallbladder Neoplasms
| Article | Year |
|---|---|
Effects of Gemcitabine and Oxaliplatin Combined with Apatinib on Immune Function and Levels of SIL-2R and sicAM-1 in Patients with Gallbladder Cancer.
Topics: Deoxycytidine; Gallbladder Neoplasms; Gemcitabine; Humans; Immunity; Oxaliplatin; Pyridines; Retrospective Studies | 2022 |
[GEM plus CDDP Combination Therapy for Unresectable Biliary Tract Cancer-A Single Institution Experience].
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gallbladder Neoplasms; Gastrointestinal Neoplasms; Gemcitabine; Humans; Male; Neutropenia; Thrombocytopenia; Treatment Outcome | 2023 |
A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF-10502-01 for the treatment of advanced solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Gallbladder Neoplasms; Gemcitabine; Humans | 2023 |
Pemetrexed and Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer Who Failed Gemcitabine-containing Chemotherapy: A Phase II Single-arm Prospective Study.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma in Situ; Cholangiocarcinoma; Erlotinib Hydrochloride; Gallbladder Neoplasms; Gemcitabine; Humans; Pemetrexed; Prospective Studies; Salvage Therapy | 2023 |
Modified gemcitabine and oxaliplatin or gemcitabine + cisplatin in unresectable gallbladder cancer: Results of a phase III randomised controlled trial.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cholecystectomy; Cisplatin; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Intention to Treat Analysis; Male; Middle Aged; Oxaliplatin; Progression-Free Survival; Survival Rate; Treatment Outcome | 2019 |
Genome-wide CRISPR screen identifies ELP5 as a determinant of gemcitabine sensitivity in gallbladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Carrier Proteins; Clustered Regularly Interspaced Short Palindromic Repeats; Cohort Studies; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Genome-Wide Association Study; Heterogeneous-Nuclear Ribonucleoproteins; Humans; Internal Ribosome Entry Sites; Male; Middle Aged; RNA Processing, Post-Transcriptional; RNA, Transfer; Tumor Suppressor Protein p53 | 2019 |
Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy o
Topics: Antineoplastic Combined Chemotherapy Protocols; Cholecystectomy; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Hepatectomy; Humans; Incidental Findings; Male; Neoadjuvant Therapy; Treatment Outcome | 2020 |
Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Global Health; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Survival Analysis | 2020 |
Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; DNA Mutational Analysis; ErbB Receptors; Gallbladder Neoplasms; Gemcitabine; Gene Amplification; Genes, erbB-1; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Mutation; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Prognosis | 2018 |
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bayes Theorem; Benzimidazoles; Bile Duct Neoplasms; Breast Neoplasms; Carboplatin; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Induction Chemotherapy; Kidney Neoplasms; Kidney Pelvis; Liver Neoplasms; Lung Neoplasms; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Mesothelioma; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms; Skin Neoplasms; Thrombocytopenia; Treatment Outcome | 2018 |
A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2013 |
Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.
Topics: Adult; Aged; Alanine Transaminase; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma; Cetuximab; Cholangiocarcinoma; Common Bile Duct Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Intention to Treat Analysis; Male; Middle Aged; Mutation; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins | 2014 |
Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2014 |
Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Biomarkers, Tumor; Chemokine CXCL12; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Quality of Life; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors | 2014 |
SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Capecitabine; Chemoradiotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Survival Rate | 2015 |
Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial
Topics: Australia; Bile Duct Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cisplatin; Denmark; Deoxycytidine; Gallbladder Neoplasms; Gemcitabine; Germany; Humans; Netherlands; Prognosis; Treatment Outcome; United Kingdom | 2015 |
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Prognosis; Proto-Oncogene Proteins p21(ras); Treatment Outcome | 2016 |
Efficacy and safety of gemcitabine-oxaliplatin combined with huachansu in patients with advanced gallbladder carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Bufanolides; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Severity of Illness Index | 2008 |
Pemetrexed and gemcitabine for biliary tract and gallbladder carcinomas: a North Central Cancer Treatment Group (NCCTG) phase I and II Trial, N9943.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Glutamates; Guanine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pemetrexed; Prognosis; Survival Rate; Treatment Outcome | 2007 |
A phase II study of gemcitabine and oxaliplatin (Oxigem) in unresectable gall bladder cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Female; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Mucositis; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome; Vomiting | 2010 |
Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2010 |
Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome; Young Adult | 2009 |
A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Thymidylate Synthase | 2011 |
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2012 |
Outpatient therapy with gemcitabine and docetaxel for gallbladder, biliary, and cholangio-carcinomas.
Topics: Adult; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Docetaxel; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Palliative Care; Survival Analysis; Taxoids | 2002 |
Gemcitabine and Cisplatin is a highly effective combination chemotherapy in patients with advanced cancer of the gallbladder.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Prospective Studies; Remission Induction; Survival Analysis | 2003 |
Concomitant gemcitabine (Gemzar) and extended nodes irradiation in the treatment of pancreatic and biliary carcinoma: a phase I study.
Topics: Aged; Bile Duct Neoplasms; Combined Modality Therapy; Common Bile Duct Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Hepatic Duct, Common; Humans; Infusions, Intravenous; Klatskin Tumor; Lymphatic Irradiation; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant | 2003 |
Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer.
Topics: Aged; Biliary Tract Neoplasms; Cholangiocarcinoma; Confidence Intervals; Deoxycytidine; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Hematologic Diseases; Humans; Karnofsky Performance Status; Male; Middle Aged; Survival Rate | 2004 |
A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Treatment Outcome | 2004 |
Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2004 |
Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Male; Middle Aged; Survival Analysis | 2005 |
A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cholangiocarcinoma; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Survival Analysis | 2004 |
Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Prognosis; Treatment Outcome | 2005 |
Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Survival Analysis; Thrombocytopenia | 2005 |
Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cholestasis, Extrahepatic; Cholestasis, Intrahepatic; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Prognosis; Survival Analysis | 2005 |
A phase II study of alternating cycles of split course radiation therapy and gemcitabine chemotherapy for inoperable pancreatic or biliary tract carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Carcinoma; Combined Modality Therapy; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Intestine, Small; Life Tables; Lymphatic Irradiation; Male; Middle Aged; Neoadjuvant Therapy; Palliative Care; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prospective Studies; Radiation Injuries; Radiation-Sensitizing Agents; Survival Analysis; Treatment Outcome | 2005 |
Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Carcinoma; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Models, Statistical; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2005 |
A Phase II study of capecitabine combined with gemcitabine in patients with advanced gallbladder carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Survival Rate | 2005 |
A phase II study of gemcitabine and carboplatin combination chemotherapy in gallbladder carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Treatment Outcome | 2006 |
Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2006 |
Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged | 2006 |
Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Survival Analysis | 2008 |
Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2007 |
A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Prospective Studies; Survival Rate; Treatment Outcome | 2007 |
A phase I trial of MTA and gemcitabine in patients with locally advanced or metastatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Enzyme Inhibitors; Female; Folic Acid Antagonists; Gallbladder Neoplasms; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Neoplasms; Pemetrexed | 1999 |
Biliary tract cancer: our experience with gemcitabine treatment.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged | 2000 |
A phase II study of gemcitabine in gallbladder carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma; Deoxycytidine; Disease-Free Survival; Female; Fever; Gallbladder Neoplasms; Gemcitabine; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Treatment Outcome | 2001 |
Toxicity of a 24-hour infusion of gemcitabine in biliary tract and pancreatic cancer: a pilot study.
Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Prostatic Neoplasms | 2002 |
Chemotherapy with gemcitabine in patients with gall-bladder carcinoma.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Deoxycytidine; Disease-Free Survival; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Neoplasm Staging; Pilot Projects; Prognosis; Survival Analysis; Treatment Outcome | 2002 |
131 other study(ies) available for gemcitabine and Gallbladder Neoplasms
| Article | Year |
|---|---|
Survival Outcomes of Gemcitabine Plus S-1 Adjuvant Chemotherapy after Surgical Resection for Advanced Biliary Tract Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Surgical Procedures; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Klatskin Tumor; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Propensity Score; Survival Rate; Tegafur | 2021 |
Epigenetic activation of the elongator complex sensitizes gallbladder cancer to gemcitabine therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Epigenomics; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Mice; Mice, Nude | 2021 |
[A Case of Gallbladder Cancer with Long Survival Treated with Resection after Downstaging with GC Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Female; Gallbladder Neoplasms; Gemcitabine; Humans | 2022 |
ELF3 promotes gemcitabine resistance through PKMYT1/CDK1 signaling pathway in gallbladder cancer.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Gallbladder Neoplasms; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; Mice; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-ets; RNA, Small Interfering; Signal Transduction; Transcription Factors | 2023 |
A Novel Gemcitabine-Resistant Gallbladder Cancer Model Provides Insights into Molecular Changes Occurring during Acquired Resistance.
Topics: Carcinoma in Situ; Cell Line, Tumor; Deoxycytidine; Gallbladder Neoplasms; Gemcitabine; Humans; Proteomics | 2023 |
YTHDF2 promotes gallbladder cancer progression and gemcitabine resistance via m6A-dependent DAPK3 degradation.
Topics: Death-Associated Protein Kinases; Gallbladder Neoplasms; Gemcitabine; Humans; RNA; RNA-Binding Proteins; Transcription Factors | 2023 |
FASN promotes gallbladder cancer progression and reduces cancer cell sensitivity to gemcitabine through PI3K/AKT signaling.
Topics: Animals; Fatty Acid Synthase, Type I; Fatty Acid Synthases; Gallbladder Neoplasms; Gemcitabine; Humans; Mice; Mice, Nude; Orlistat; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt | 2023 |
α-Mangostin suppresses the de novo lipogenesis and enhances the chemotherapeutic response to gemcitabine in gallbladder carcinoma cells via targeting the AMPK/SREBP1 cascades.
Topics: AMP-Activated Protein Kinases; Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Cycle Checkpoints; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Synergism; Drug Therapy, Combination; Gallbladder Neoplasms; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lipogenesis; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Sterol Regulatory Element Binding Protein 1; Tumor Cells, Cultured; Xanthones; Xenograft Model Antitumor Assays | 2020 |
Long non-coding RNA SSTR5-AS1 facilitates gemcitabine resistance via stabilizing NONO in gallbladder carcinoma.
Topics: Animals; Apoptosis; Cell Line, Tumor; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gallbladder Neoplasms; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Nude; Proteasome Endopeptidase Complex; Protein Stability; Proteolysis; RNA-Binding Proteins; RNA, Long Noncoding; Up-Regulation | 2020 |
UCP2 promotes proliferation and chemoresistance through regulating the NF-κB/β-catenin axis and mitochondrial ROS in gallbladder cancer.
Topics: Animals; Antineoplastic Agents; beta Catenin; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gallbladder Neoplasms; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Iridoids; Male; Mice; Mice, Nude; Mitochondria; Neoplasms, Experimental; NF-kappa B; Reactive Oxygen Species; Uncoupling Protein 2; Up-Regulation | 2020 |
High infiltration of mast cells is associated with improved response to adjuvant chemotherapy in gallbladder cancer.
Topics: Antimetabolites, Antineoplastic; CD8-Positive T-Lymphocytes; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Interferon-gamma; Lymphocytes, Tumor-Infiltrating; Male; Mast Cells; Middle Aged; Prognosis; Signal Transduction | 2020 |
Functional and genomic characterization of three novel cell lines derived from a metastatic gallbladder cancer tumor.
Topics: Animals; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Agents; Ascitic Fluid; Carcinogenesis; Carcinogenicity Tests; Cell Line, Tumor; Chile; Cisplatin; Clone Cells; Deoxycytidine; DNA Fingerprinting; Epithelial Cells; Gallbladder Neoplasms; Gemcitabine; Gene Expression Profiling; Genes, erbB-2; Humans; Indians, South American; Keratin-19; Keratin-7; Male; Mice, Inbred NOD; Middle Aged; Receptor, ErbB-2; Sequence Analysis, RNA; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2020 |
Inhibition of autophagy by chloroquine enhances the antitumor activity of gemcitabine for gallbladder cancer.
Topics: Animals; Antimalarials; Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Cell Proliferation; Chloroquine; Deoxycytidine; Drug Synergism; Drug Therapy, Combination; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Overexpression of microRNA-205-5p exerts suppressive effects on stem cell drug resistance in gallbladder cancer by down-regulating PRKCE.
Topics: Adult; Aged; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Cholecystectomy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gallbladder; Gallbladder Neoplasms; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Healthy Volunteers; HEK293 Cells; Humans; Male; Mice; MicroRNAs; Middle Aged; Neoplastic Stem Cells; Protein Kinase C-epsilon; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
HDAC6 inhibitor, ACY1215 suppress the proliferation and induce apoptosis of gallbladder cancer cells and increased the chemotherapy effect of gemcitabine and oxaliplatin.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Gallbladder Neoplasms; Gemcitabine; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Humans; Oxaliplatin; Tumor Cells, Cultured | 2021 |
[A Case of Gallbladder Cancer with Para-Aortic Lymph Node Metastasis Successfully Treated by Gemcitabine plus Cisplatin Combination Chemotherapy and Conversion Surgery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged | 2020 |
Calreticulin: a potential diagnostic and therapeutic biomarker in gallbladder cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Calreticulin; Cell Line, Tumor; Cholecystitis; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Mice, Nude; Middle Aged; Molecular Targeted Therapy; Oncogenes; Prognosis; Random Allocation; Xenograft Model Antitumor Assays | 2021 |
GLI2 but not GLI1/GLI3 plays a central role in the induction of malignant phenotype of gallbladder cancer.
Topics: Aged; Animals; B7-H1 Antigen; Biomarkers, Tumor; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Epithelial-Mesenchymal Transition; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Lymphocytes, Tumor-Infiltrating; Male; Mice; Middle Aged; Nuclear Proteins; Prognosis; Signal Transduction; Zinc Finger Protein Gli2 | 2021 |
Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bile Duct Neoplasms; Biomarkers, Tumor; Cholangiocarcinoma; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Palliative Care; Platinum; Prognosis; Survival Analysis; Treatment Outcome | 2021 |
MCL1 participates in leptin-promoted mitochondrial fusion and contributes to drug resistance in gallbladder cancer.
Topics: Adipocytes; Animals; Antimetabolites, Antineoplastic; Apoptosis Regulatory Proteins; CCAAT-Enhancer-Binding Protein-delta; Deoxycytidine; Drug Discovery; Drug Resistance, Neoplasm; Gallbladder Neoplasms; Gemcitabine; Leptin; Mice; Mice, Inbred NOD; Mice, SCID; Mitochondrial Dynamics; Myeloid Cell Leukemia Sequence 1 Protein; STAT3 Transcription Factor | 2021 |
miR-218-5p restores sensitivity to gemcitabine through PRKCE/MDR1 axis in gallbladder cancer.
Topics: ATP Binding Cassette Transporter, Subfamily B; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Neoplasm Proteins; Protein Kinase C-epsilon; RNA, Neoplasm; Up-Regulation | 2017 |
Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Prognosis; Republic of Korea; Retrospective Studies; Sex Factors; Treatment Outcome | 2017 |
Effect of Adjuvant Gemcitabine Combined with Low-dose 5-Fluorouracil and Cisplatin Chemotherapy for Advanced Biliary Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Hepatectomy; Humans; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2017 |
Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Palliative Care; Treatment Outcome | 2018 |
[Long-Term Survival after Resection for Repeated Abdominal Wall Recurrence of Gallbladder Cancer].
Topics: Abdominal Neoplasms; Abdominal Wall; Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Recurrence; Time Factors | 2017 |
Gemcitabine-cisplatin (GC) as adjuvant chemotherapy in resected stage II and stage III gallbladder cancers (GBC): a potential way forward.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Retrospective Studies | 2018 |
Guided chemotherapy based on patient-derived mini-xenograft models improves survival of gallbladder carcinoma patients.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Oxaliplatin; Paclitaxel; Xenograft Model Antitumor Assays | 2018 |
Gallbladder Carcinosarcoma with Mirizzi Syndrome: a Rare Presentation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chemotherapy, Adjuvant; Cholecystectomy, Laparoscopic; Cisplatin; Deoxycytidine; Gallbladder; Gallbladder Neoplasms; Gemcitabine; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Mirizzi Syndrome; Treatment Outcome | 2019 |
Hesperidin Induces ROS-Mediated Apoptosis along with Cell Cycle Arrest at G2/M Phase in Human Gall Bladder Carcinoma.
Topics: Acetylcysteine; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Cycle Checkpoints; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Gallbladder Neoplasms; Gemcitabine; Hesperidin; Humans; Macrophages; Membrane Potential, Mitochondrial; Mice; Reactive Oxygen Species; Tumor Cells, Cultured | 2019 |
Synchronous Adeno-squamous Carcinoma of Gallbladder and Adenocarcinoma of Common Bile Duct: Twin Trouble.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cholecystectomy, Laparoscopic; Cisplatin; Common Bile Duct; Deoxycytidine; Gallbladder; Gallbladder Neoplasms; Gemcitabine; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms, Multiple Primary; Pancreaticojejunostomy; Treatment Outcome; Ultrasonography | 2019 |
[A Case of Advanced Gallbladder Cancer with Paraaortic Lymph Node Metastases Successfully Treated by Chemotherapy and Conversion Surgery].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gallbladder Neoplasms; Gemcitabine; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Positron Emission Tomography Computed Tomography | 2018 |
Second-line chemotherapy in biliary tract cancer: Outcome and prognostic factors.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Prognosis; Prospective Studies; Survival Analysis; Treatment Outcome | 2019 |
aPKCι promotes gallbladder cancer tumorigenesis and gemcitabine resistance by competing with Nrf2 for binding to Keap1.
Topics: Animals; Antioxidants; Cell Line, Tumor; Cell Transformation, Neoplastic; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gallbladder Neoplasms; Gemcitabine; Gene Knockdown Techniques; Humans; Kelch-Like ECH-Associated Protein 1; Mice; Models, Biological; NF-E2-Related Factor 2; Prognosis; Protein Binding; Protein Interaction Domains and Motifs; Protein Kinase C; Reactive Oxygen Species; Signal Transduction | 2019 |
Pretreatment with Gemcitabine/5-Fluorouracil Enhances the Cytotoxicity of Trastuzumab to HER2-Negative Human Gallbladder Cancer Cells In Vitro and In Vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2019 |
Prognosis and prognostic factors in patients with advanced biliary tract cancer depending on its anatomical location.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Palliative Care; Prognosis; Republic of Korea; Retrospective Studies | 2019 |
Radiotherapy or Chemoradiation in Unresectable Biliary Cancer: A Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Brachytherapy; Chemoradiotherapy; Cholangiocarcinoma; Deoxycytidine; Dose Fractionation, Radiation; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Klatskin Tumor; Male; Middle Aged; Neoplasm Staging; Progression-Free Survival; Retrospective Studies; Risk Factors; Time Factors | 2019 |
[Remarkable tumor response to cisplatin plus gemcitabine therapy in a patient with recurrent gallbladder cancer - a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Neoplasm Staging; Recurrence | 2013 |
Small cell gall bladder carcinoma complicated by syndrome of inappropriate secretion of antidiuretic hormone (SIADH) treated with mozavaptan.
Topics: Antidiuretic Hormone Receptor Antagonists; Antimetabolites, Antineoplastic; Benzazepines; Carcinoma, Small Cell; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Inappropriate ADH Syndrome; Middle Aged; Treatment Outcome | 2013 |
Combination chemotherapy of nafamostat mesylate with gemcitabine for gallbladder cancer targeting nuclear factor-κB activation.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Benzamidines; Carcinoma; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Therapy, Combination; Gallbladder Neoplasms; Gemcitabine; Guanidines; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Serine Proteinase Inhibitors; Xenograft Model Antitumor Assays | 2013 |
[A case of initially unresectable gallbladder cancer with surgical resection after chemotherapy with gemcitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Staging; Remission Induction | 2013 |
[A case of effective multidisciplinary treatment for advanced gallbladder carcinoma with distant lymph node metastases].
Topics: Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Oxonic Acid; Quality of Life; Tegafur | 2013 |
[A case of long-term survival after aggressive surgery for Stage IV gallbladder carcinoma].
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Neoplasm Staging | 2013 |
Potential biomarkers for sensitivity of gallbladder cancer cells to gemcitabine.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gallbladder Neoplasms; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Oligonucleotide Array Sequence Analysis; Real-Time Polymerase Chain Reaction; Signal Transduction | 2014 |
Gemcitabine-induced hemolytic uremic syndrome mimicking scleroderma renal crisis presenting with Raynaud's phenomenon, positive antinuclear antibodies and hypertensive emergency.
Topics: Antibodies, Antinuclear; Blood Pressure; Deoxycytidine; Diagnosis, Differential; Emergencies; Female; Gallbladder Neoplasms; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Hypertension, Malignant; Immunosuppressive Agents; Kidney Glomerulus; Middle Aged; Raynaud Disease; Ribonucleotide Reductases; Scleroderma, Systemic | 2014 |
Phenoxodiol enhances the antitumor activity of gemcitabine in gallbladder cancer through suppressing Akt/mTOR pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Female; G1 Phase Cell Cycle Checkpoints; Gallbladder Neoplasms; Gemcitabine; Humans; Isoflavones; Mice; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Resting Phase, Cell Cycle; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2014 |
Gemcitabine-based adjuvant chemotherapy for patients with advanced gallbladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Prognosis; Retrospective Studies; Survival Rate; Tegafur | 2014 |
Cordycepin down-regulates multiple drug resistant (MDR)/HIF-1α through regulating AMPK/mTORC1 signaling in GBC-SD gallbladder cancer cells.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Deoxyadenosines; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Signal Transduction; TOR Serine-Threonine Kinases | 2014 |
Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Capecitabine; Carboplatin; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2014 |
A report of sarcomatoid carcinoma of the gallbladder treated with palliative deocetaxel and gemcitabine chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Radiography; Taxoids | 2014 |
Curative resection of gallbladder cancer with liver invasion and hepatic metastasis after chemotherapy with gemcitabine plus S-1: report of a case.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cholecystectomy; Deoxycytidine; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Tegafur | 2014 |
Hispidulin inhibits proliferation and enhances chemosensitivity of gallbladder cancer cells by targeting HIF-1α.
Topics: Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Flavones; Fluorouracil; G1 Phase Cell Cycle Checkpoints; Gallbladder Neoplasms; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice, Inbred BALB C; Mice, Nude; Signal Transduction; Transcriptional Activation; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Maslinic acid potentiates the antitumor activities of gemcitabine in vitro and in vivo by inhibiting NF-κB-mediated survival signaling pathways in human gallbladder cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Cell Line, Tumor; Cell Movement; Deoxycytidine; Drug Synergism; Gallbladder Neoplasms; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Proteins; NF-kappa B; Random Allocation; Signal Transduction; Triterpenes; Xenograft Model Antitumor Assays | 2015 |
[A case of advanced gallbladder cancer with mediastinum lymph node metastasis successfully treated with multimodality therapy].
Topics: Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Lymphatic Metastasis; Mediastinal Neoplasms; Tegafur; Uracil | 2014 |
Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis | 2015 |
Use of gemcitabine-platinum in Indian patients with advanced gall bladder cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; India; Insecticide-Treated Bednets; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
Acquisition of chemoresistance to gemcitabine is induced by a loss-of-function missense mutation of DCK.
Topics: Amino Acid Substitution; Antineoplastic Agents; Base Sequence; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; DNA Damage; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; Exons; Gallbladder Neoplasms; Gemcitabine; Gene Deletion; Humans; Mutation, Missense | 2015 |
Low expression of equilibrative nucleoside transporter 1 is associated with poor prognosis in chemotherapy-naïve pT2 gallbladder adenocarcinoma patients.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gallbladder; Gallbladder Neoplasms; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Survival Analysis | 2016 |
FOLFOX-4 as second-line therapy after failure of gemcitabine and platinum combination in advanced gall bladder cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Platinum Compounds; Treatment Failure; Treatment Outcome | 2016 |
[Resection of Initially Unresectable Gallbladder Cancer with Multiple Liver Metastases after Chemotherapy with Gemcitabine plus Cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Prognosis | 2015 |
[Unresectable Gallbladder Cancer Successfully Treated with Gemcitabine Chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Gallbladder Neoplasms; Gemcitabine; Hepatic Artery; Humans; Jaundice, Obstructive; Male; Stents; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
[A Case of Successful Curative Resection Following Downsizing Chemotherapy in Initially Unresectable Locally Advanced Gallbladder Carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Neoplasm Staging; Treatment Outcome | 2015 |
Second-Line Palliative Chemotherapy in Advanced Gall Bladder Cancer, CAP-IRI: Safe and Effective Option.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Hydrocarbons, Chlorinated; Male; Middle Aged; Palliative Care; Prognosis; Prospective Studies; Retrospective Studies | 2016 |
Carcinoma of Gall bladder with distant metastasis to breast parenchyma. Report of a case and review of literature.
Topics: Adult; Breast Neoplasms; Carboplatin; Carcinoma; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Neoplasm Metastasis; Palliative Medicine | 2016 |
A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chemoradiotherapy; Cholangiocarcinoma; Cisplatin; Combined Modality Therapy; Common Bile Duct Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Klatskin Tumor; Male; Middle Aged; Pilot Projects; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Unstable Angina: A Serious Adverse Event following Gemcitabine-Cisplatin Based Chemotherapy.
Topics: Adenocarcinoma; Adult; Angina, Unstable; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Fatal Outcome; Gallbladder Neoplasms; Gemcitabine; Humans; Male | 2016 |
Granulocyte Colony-Stimulating Factor-Producing Gallbladder Cancer.
Topics: Adenocarcinoma, Papillary; Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged | 2016 |
[Two Cases of Unresectable Advanced Gallbladder Cancer in Which Gemcitabine and Cisplatin Therapy Improved the QOL].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Fatal Outcome; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Treatment Outcome | 2016 |
A retrospective analysis of the clinical effects of neoadjuvant combination therapy with full-dose gemcitabine and radiation therapy in patients with biliary tract cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Biliary Tract Neoplasms; Chemoradiotherapy; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Female; Gallbladder Neoplasms; Gemcitabine; Hepatectomy; Humans; Klatskin Tumor; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreaticoduodenectomy; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed | 2017 |
[Radical Resection of cT3a Gallbladder Cancer after Neoadjuvant Chemotherapy - A Case Report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cholecystitis, Acute; Cisplatin; Deoxycytidine; Gallbladder Neoplasms; Gemcitabine; Humans; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Neoplasm Staging | 2016 |
[A Case of Surgical Resection for Gallbladder Cancer with Para-Aortic Lymph Node Metastasis Following Neoadjuvant Chemotherapy with Gemcitabine, Cisplatin, and TS-1].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Lymphatic Metastasis; Neoadjuvant Therapy; Silicates; Titanium | 2016 |
[A Case of Locally Advanced Gallbladder Cancer That Developed Early Multiple Liver Metastasis after Curative Resection, and Achieved Long-TermPartial Remission Using S-1 and Gemcitabine].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Oxonic Acid; Tegafur; Treatment Outcome | 2016 |
[A Long-Surviving Case of Unresectable Gall Bladder Carcinoma Treated with Gemcitabine-Based Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fatal Outcome; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Time Factors | 2016 |
[A Case of Metachronous Liver Metastases of Gall Bladder Cancer Successfully Treated by Liver Resection].
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Cholecystectomy; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms | 2016 |
Gemcitabine-cisplatin versus gemcitabine-oxaliplatin doublet chemotherapy in advanced gallbladder cancers: a match pair analysis.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Female; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Immunosuppressive Agents; India; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Time Factors; Treatment Outcome | 2017 |
Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma.
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Biliary Tract Neoplasms; Biomarkers, Tumor; Blotting, Western; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Flow Cytometry; Gallbladder Neoplasms; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; RNA, Neoplasm; RNA, Small Interfering; Transfection; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2008 |
[A case of recurrent gall bladder cancer responding to chemotherapy with gemcitabine after endoscopic metallic biliary stent implantation].
Topics: Aged; Deoxycytidine; Endoscopes; Gallbladder Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Male; Metals; Recurrence; Stents; Tomography, X-Ray Computed | 2008 |
Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Cholecystectomy; Cholecystectomy, Laparoscopic; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Hepatectomy; Humans; Incidental Findings; Male; Middle Aged; Neoplasm, Residual; Neuroendocrine Tumors; Radiotherapy, Adjuvant; Retrospective Studies; Sarcoma; Survival Analysis | 2008 |
Resection of gallbladder cancer with hepatic metastasis after chemotherapy with gemcitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Deoxycytidine; Gallbladder Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Male; Tomography, X-Ray Computed | 2008 |
In vivo chemotherapeutic profile of human gallbladder small cell carcinoma.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Docetaxel; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Organoplatinum Compounds; Taxoids; Xenograft Model Antitumor Assays | 2008 |
Schedule-dependent synergistic interaction between gemcitabine and oxaliplatin in human gallbladder adenocarcinoma cell lines.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Count; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Synergism; Gallbladder Neoplasms; Gemcitabine; Humans; Inhibitory Concentration 50; Organoplatinum Compounds; Oxaliplatin; Time Factors | 2009 |
Gallbladder carcinoma presenting as a pelvic mass with elevated serum testosterone: a case report.
Topics: Abdominal Pain; Adenocarcinoma; Antineoplastic Agents; CA-125 Antigen; Cholecystectomy; Cisplatin; Deoxycytidine; Diagnosis, Differential; Fallopian Tubes; Fatal Outcome; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Hysterectomy; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Testosterone; Tomography, X-Ray Computed; Ultrasonography | 2009 |
Fatal gemcitabine-induced pulmonary toxicity in metastatic gallbladder adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Fatal Outcome; Gallbladder Neoplasms; Gemcitabine; Humans; Lung Diseases, Interstitial; Male; Neoplasm Metastasis | 2010 |
A case of unresectable gallbladder cancer responding to gemcitabine after metallic biliary stent implantation.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Drainage; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Metals; Radiography; Stents | 2009 |
[A case of long-term survival for advanced gallbladder cancer].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cholecystectomy; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged | 2009 |
Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance.
Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Proto-Oncogene Proteins c-akt; Pteridines; Pyrimidines; Pyrroles; Receptor, IGF Type 1 | 2010 |
Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cetuximab; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Survival Rate | 2010 |
Outcome of patients receiving chemotherapy for advanced biliary tract or gallbladder carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2010 |
Ovarian metastasis following gallbladder carcinoma: a case report.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Incidental Findings; Lymph Node Excision; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Ovariectomy; Oxaliplatin; Treatment Outcome | 2010 |
Adjuvant chemoradiation therapy in gallbladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Long-term administration of Wilms tumor-1 peptide vaccine in combination with gemcitabine causes severe local skin inflammation at injection sites.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Cancer Vaccines; Cell Cycle Proteins; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Dermatitis; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Injections, Intradermal; Liver Neoplasms; Lymphocytes; Nuclear Proteins; Palliative Care; Radiotherapy, Adjuvant; RNA Splicing Factors; Skin | 2010 |
Chemoradiation for unresectable gall bladder cancer: time to review historic nihilism?
Topics: Adult; Antimetabolites, Antineoplastic; Chemoradiotherapy; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Middle Aged; Prospective Studies; Treatment Outcome | 2011 |
[A case of gallbladder cancer which completely responded to gemcitabine].
Topics: Aged; Combined Modality Therapy; Deoxycytidine; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Neoplasm Staging; Remission Induction; Tomography, X-Ray Computed | 2010 |
Simultaneous breast and ovarian metastasis from gallbladder carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Cholecystectomy; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Mastectomy; Middle Aged; Ovarian Neoplasms; Ovariectomy; Salpingectomy | 2010 |
[A long-term survivor treated with S-1 and gemcitabine for recurrence following an operation for advanced gall bladder cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Fatal Outcome; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Neoplasm Staging; Oxonic Acid; Recurrence; Tegafur; Time Factors; Tomography, X-Ray Computed | 2010 |
CD44+ CD133+ population exhibits cancer stem cell-like characteristics in human gallbladder carcinoma.
Topics: AC133 Antigen; Animals; Antigens, CD; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Glycoproteins; Humans; Hyaluronan Receptors; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Oncogene Proteins; Peptides; Spheroids, Cellular; Trans-Activators; Up-Regulation; Zinc Finger Protein GLI1 | 2010 |
Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report.
Topics: Aged; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Deoxycytidine; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gallbladder Neoplasms; Gemcitabine; Humans; Lymphatic Metastasis; Male; Mutation; Positron-Emission Tomography; Quinazolines; Treatment Outcome | 2010 |
Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Blotting, Western; Carcinoma; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gallbladder Neoplasms; Gemcitabine; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Intracellular Signaling Peptides and Proteins; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Receptor, ErbB-2; Signal Transduction | 2010 |
[Evaluation of systemic chemotherapy for unresectable gallbladder carcinoma].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Retrospective Studies; Survival Analysis; Tegafur | 2010 |
[A case of unresectable advanced gallbladder cancer successfully treated by a combined administration of gemcitabine + CDDP].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged | 2010 |
Prognostic factors of patients with advanced gallbladder carcinoma following aggressive surgical resection.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; Cholecystectomy; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Hepatectomy; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Pancreaticoduodenectomy; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate | 2011 |
Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: role of uric acid accumulation in gemcitabine-induced MICA/B expression.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Death; Cell Line, Tumor; Cytotoxicity, Immunologic; Deoxycytidine; DNA Damage; Female; Gallbladder Neoplasms; Gemcitabine; Gene Expression; Histocompatibility Antigens Class I; Humans; Kaplan-Meier Estimate; Killer Cells, Natural; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Peritoneal Neoplasms; Uric Acid; Xanthine Dehydrogenase | 2011 |
[Advanced gallbladder cancer that showed complete response to gemcitabine plus S-1 chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Gallbladder Neoplasms; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Tegafur | 2011 |
Adjuvant radio-chemotherapy after extended or simple cholecystectomy in gallbladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Capecitabine; Chemotherapy, Adjuvant; Cholecystectomy; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Radiotherapy, Adjuvant; Survival Rate; Tegafur; Treatment Outcome; Uracil | 2011 |
Biliary-tract cancer: improving therapy by adding molecularly targeted agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Erlotinib Hydrochloride; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2012 |
[Curative resection of gallbladder cancer with simultaneous liver metastasis].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gallbladder Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Tegafur | 2011 |
The therapeutic effect of histone deacetylase inhibitor PCI-24781 on gallbladder carcinoma in BK5.erbB2 mice.
Topics: Animals; Antimetabolites, Antineoplastic; Benzofurans; Carcinoma; Carrier Proteins; Cell Division; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Gallbladder; Gallbladder Neoplasms; Gemcitabine; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Intracellular Signaling Peptides and Proteins; Mice; Mice, Mutant Strains; Mucin-4; Phosphorylation; RNA, Messenger | 2012 |
Prognostic significance of aquaporins in human biliary tract carcinoma.
Topics: Aged; Aged, 80 and over; Aquaporin 1; Aquaporin 4; Aquaporin 5; Aquaporins; Bile Duct Neoplasms; Biomarkers, Tumor; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Prognosis; Tegafur | 2012 |
Guggulsterone enhances antitumor activity of gemcitabine in gallbladder cancer cells through suppression of NF-κB.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Synergism; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Matrix Metalloproteinase 2; Neoplasm Invasiveness; NF-kappa B; Pregnenediones; Vascular Endothelial Growth Factor C | 2012 |
Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma - a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Capecitabine; Carcinoma; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies | 2012 |
Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: a retrospective single-center study.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Carcinoma; Cholangiocarcinoma; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Retrospective Studies; Treatment Outcome | 2013 |
Icariin potentiates the antitumor activity of gemcitabine in gallbladder cancer by suppressing NF-κB.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Drugs, Chinese Herbal; Female; Flavonoids; Gallbladder; Gallbladder Neoplasms; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; NF-kappa B | 2013 |
Improvement of prognosis for unresectable biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biliary Tract Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2013 |
Neuroendocrine tumor of the gallbladder.
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Catheter Ablation; Cisplatin; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Female; Gallbladder; Gallbladder Neoplasms; Gemcitabine; Humans; Indoles; Middle Aged; Pyrroles; Sunitinib; Taxoids; Ultrasonography | 2013 |
Palliative chemotherapy with gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in metastatic biliary tract and gall bladder adenocarcinomas.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Drug Administration Schedule; Fatal Outcome; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Palliative Care | 2003 |
[A case of inoperable advanced gallbladder cancer that has maintained stable disease status for a long period with gemcitabine and cisplatin therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Middle Aged; Quality of Life; Survivors; Tomography, X-Ray Computed | 2004 |
[A case of successful treatment with combined 5-fluorouracil, adriamycin, cisplatin (FAP) therapy followed by Gemcitabine, UFT therapy and intra-arterial FAP therapy for unresectable advanced gallbladder cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Middle Aged; Tegafur; Uracil | 2004 |
[A patient with recurrent gallbladder cancer responding to chemotherapy with CDDP/CPT-11 and gemcitabine].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Neoplasm Recurrence, Local; Survivors | 2005 |
Cisplatin and gemcitabine for small cell carcinoma of the gall bladder.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; Fatal Outcome; Gallbladder Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged | 2005 |
[Two cases of advanced gallbadder cancer with para-aortic lymph node metastasis responding to intra-aortic infusion of gemcitabine and low-dose CDDP/5-FU].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Infusions, Intra-Arterial; Lymph Nodes; Lymphatic Metastasis; Middle Aged | 2005 |
Gallbladder cancer, a different disease that needs individual trials.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gallbladder Neoplasms; Gallstones; Gemcitabine; Hemorrhage; Humans; Research Design; Treatment Outcome | 2005 |
[A case report of unresectable gallbladder cancer that responded remarkably to the combination of thalidomide, celecoxib, and gemcitabine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Deoxycytidine; Drug Administration Schedule; Gallbladder Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Male; Neoplasm Invasiveness; Peritoneal Neoplasms; Prognosis; Pyrazoles; Remission Induction; Sulfonamides; Thalidomide | 2006 |
Antitumor effect of gemcitabine on orthotopically inoculated human gallbladder cancer cells in nude mice.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Bile Duct Neoplasms; Cell Proliferation; Deoxycytidine; Gallbladder Neoplasms; Gemcitabine; Humans; In Situ Nick-End Labeling; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Proliferating Cell Nuclear Antigen; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2007 |
Establishment of a novel orthotopic xenograft model of human gallbladder carcinoma.
Topics: Animals; Deoxycytidine; Disease Models, Animal; Gallbladder Neoplasms; Gemcitabine; Humans; Keratin-7; Keratin-8; Ki-67 Antigen; Neoplasm Transplantation; Transplantation, Heterologous | 2007 |
Upregulation of topoisomerase IIalpha expression in advanced gallbladder carcinoma: a potential chemotherapeutic target.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma; Cell Proliferation; Deoxycytidine; DNA Topoisomerases, Type II; DNA-Binding Proteins; Doxorubicin; Etoposide; Female; Gallbladder Neoplasms; Gemcitabine; Gene Expression; Gene Expression Profiling; Humans; Idarubicin; Immunohistochemistry; Male; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Up-Regulation | 2008 |
An iatrogenic hepatic subcapsular biloma successfully treated by percutaneous drainage and endoscopic biliary stenting.
Topics: Adenocarcinoma; Aged; Bile; Cholangiopancreatography, Endoscopic Retrograde; Combined Modality Therapy; Deoxycytidine; Diagnostic Imaging; Drainage; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Iatrogenic Disease; Magnetic Resonance Imaging; Male; Risk Assessment; Stents; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
[Recurrent gallbladder carcinoma treated with combination chemotherapy with gemcitabine, CPT-11 and S-1--a successful case with metastatic tumors replaced by marked calcification].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Calcinosis; Camptothecin; Deoxycytidine; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Irinotecan; Liver Neoplasms; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2008 |
Efficacy of gemcitabine in the treatment of patients with gallbladder carcinoma: a case report.
Topics: Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Krukenberg Tumor; Liver Neoplasms; Peritoneal Neoplasms; Tomography, X-Ray Computed | 1998 |
Efficacy of gemcitabine in the treatment of patients with gallbladder carcinoma: a case report.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gallbladder Neoplasms; Gemcitabine; Humans | 1998 |
Chemotherapy with gemcitabine in patients with advanced gallbladder carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Cholecystectomy; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Treatment Outcome | 2000 |
[Efficacy of gemcitabine in the gallbladder cancer. Initial experience in 4 cases].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Fatal Outcome; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Tomography, X-Ray Computed; Treatment Outcome | 2000 |
[Therapy of gallbladder carcinoma. Experience of a central hospital].
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cholecystectomy; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Mitomycin; Palliative Care; Postoperative Care; Regression Analysis; Survival Analysis; Time Factors | 2002 |